Profile of inhaled levodopa and its potential in the treatment of Parkinson's disease: evidence to date

Inhaled levodopa is a newly emerging therapeutic option in the treatment of "off " symptoms associated with Parkinson's disease (PD). Its mode of delivery offers more rapid absorption of levodopa and shorter onset of clinical benefit compared to oral formulations, and has been shown t...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychiatric disease and treatment 2018-01, Vol.14, p.2955-2964
Main Authors: Patel, Ami B, Jimenez-Shahed, Joohi
Format: Article
Language:English
Subjects:
Asthma
Asthmatic persons
Comparative literature
Dopamine
Drug dosages
Drug therapy
dry powder inhalation
Dyskinesia
Health aspects
L-dopa
levodopa
Metabolism
motor fluctuations
Nausea
Nervous system
Neurology
Parkinson's disease
Patients
Respiratory tract diseases
Review
Short term
Smokers
Spirometry
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhaled levodopa is a newly emerging therapeutic option in the treatment of "off " symptoms associated with Parkinson's disease (PD). Its mode of delivery offers more rapid absorption of levodopa and shorter onset of clinical benefit compared to oral formulations, and has been shown to be feasible for use in patients with PD experiencing worse motor function due to declining plasma levodopa levels. Clinical development of this compound is supported by preclinical, Phase I-III, long-term-safety studies and studies in special populations, including otherwise-healthy asthmatics and smokers. These investigations demonstrated that the drug is well tolerated without risk of long-term (up to 1 year) changes in pulmonary function or spirometry measures. The most common side effects among PD patients were a mild cough, upper respiratory tract infection, nausea, sputum discoloration, and dyskinesia. Inhaled levodopa offers a different administration method and side-effect profile from the currently available options for rescue therapy for Off periods in PD, though comparative studies have not been performed. The drug is presently under review by the US Food and Drug Administration.
ISSN:1176-6328
1178-2021
1178-2021
DOI:10.2147/NDT.S147633